CD274 and neoplasm: Alspach and colleagues showed that the presence of tumor Ag–specific cells, specifically among CD4 TILs, was necessary for tumor regression after immunotherapy by PD-1/PD-L1 axis blockade in a mouse model (6), suggesting that PD-1 blockade directly targets PD-1+ CD4 TILs.